Clinical trialNCT04080284CompletedPhase 2Interventional

Trial of Maintenance With Niraparib- Uterine Serous Carcinoma

SponsorNorthwell HealthEnrollment22Cancer of the EndometriumEndometrial CancerEndometrial CarcinomaPapillary Serous Endometrial CarcinomaUterine Serous Carcinoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Uterine serous carcinoma (USC) accounts for up to 40% of endometrial cancer-related deaths. Patients with USC share many genomic and clinical characteristics with patients who has serous ovarian cancer. The objective of this study is to evaluate the efficacy of maintenance Niraparib regimen in patients with advanced or platinum sensitive recurrent uterine serous carcinoma. Additionally, the investigators aim to further describe the safety of this regimen. The investigators hypothesize that Niraparib maintenance will be a well-tolerated treatment and show significant response in patients with uterine serous carcinoma.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Marina Frimer, MD
Northwell Health
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Rutgers Nj School of Medicine
Newark, New Jersey, United States
Imbert Cancer Center Northwell Health
Bay Shore, New York, United States
Greenlawn Cancer Institute, Northwell Health
Greenlawn, New York, United States
Rj Zuckerberg Cancer Hospital
New Hyde Park, New York, United States
Cancer Institute at Lenox Hill
New York, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Niraparib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Dec 2019
Primary completion: 1 Jan 2025
Completion: 1 Jan 2025
Last update posted: 19 Aug 2025
Registered enrollment: 22
Registry id: NCT04080284

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.